In patients on CTLA-4 inhibitors, the cancer type of melanoma was positively associated with the risk of severe cases [B = 3.607, OR 36.873, 95% CI (1.833–741.761), p = 0.018]. This evidence concerns the gene CTLA4 and melanoma.